C4 Therapeutics (CCCC) Operating Leases (2019 - 2026)

C4 Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $51.9 million for Q1 2026.

• In Q1 2026, Operating Leases fell 11.16% year-over-year to $51.9 million; the TTM figure through Mar 2026 stood at $51.9 million (down 11.16% YoY), while the FY2025 annual figure was $53.6 million, down 10.61% from the prior year.
• Operating Leases was $51.9 million for Q1 2026 at C4 Therapeutics, down from $53.6 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $75.2 million in Q2 2022 to a low of $51.9 million in Q1 2026.
• Historically, Operating Leases has averaged $64.1 million across 5 years, with a median of $64.4 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Operating Leases soared 569.59% in 2022, then fell 11.16% in 2026.
• A 5-year view of Operating Leases shows it stood at $71.0 million in 2022, then fell by 7.35% to $65.8 million in 2023, then fell by 8.78% to $60.0 million in 2024, then slipped by 10.61% to $53.6 million in 2025, then fell by 3.15% to $51.9 million in 2026.
• The last three Operating Leases figures came in at $51.9 million (Q1 2026), $53.6 million (Q4 2025), and $55.2 million (Q3 2025), per Business Quant data.